This study compared clinical features and protein expression profiles in differentiated thyroid tumours to identify protein markers with the potential for indicating malignancy status. Tissue microarrays were constructed using 119 thyroid tumour samples (45 papillary carcinomas, 26 follicular carcinomas, 48 adenomas). Generally, there was overexpression of proliferating cell nuclear antigen (PCNA), p53, matrix metalloproteinase (MMP)-7, Hector Battifora mesothelial-1 (HBME-1), MMP-2, pituitary tumour-transforming gene (PTTG) and human telomerase reverse transcriptase (hTERT) in malignant thyroid carcinomas, and overexpression of fragile histidine triad (FHIT), p16 and Ecadherin in thyroid adenomas. Multiple factor binary logistic regression analysis indicated that MMP-2, HBME-1, p16 and FHIT were independently related to differentiated thyroid tumours. Receiveroperating characteristics for these four factors showed HBME-1 as best for diagnostic accuracy. Sensitivity and specificity were enhanced using an HBME-1 and p16 cluster. HBME-1 expression was not significantly different for papillary and follicular carcinomas, whereas p16 expression was significantly specific.
Introduction
Thyroid neoplasms are very common endocrine tumours, however it is sometimes difficult to distinguish between benign and malignant neoplasms because similar clinical manifestations are frequently encountered during intumescence colour imaging
investigations. Numerous researchers have demonstrated the value of histopathological criteria in predicting whether thyroid neoplasms are benign or malignant, however difficulties remain in distinguishing between some malignant and benign differentiated thyroid tumours. 1
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The diagnostic value of a number of immunohistochemical stains has been studied in thyroid neoplasms, for example fragile histidine triad (FHIT), metalloproteinase (MMP)-2, MMP-7, p53, p16, pituitary tumour-transforming gene (PTTG) and proliferating cell nuclear antigen (PCNA). These stains have been validated as simple, reliable and repeatable markers for use in the diagnosis of malignant and benign thyroid tumours in humans. 2 -5 Some have also been shown to be prognostically relevant in other types of tumour. 2 However, no consistent correlations of diagnostic value have been identified between these cancer/anti-cancer proteins and tumour histopathology. 3, 5 In addition, multi-protein profiling using immunohistochemical analysis of tissue has been shown to be an efficient, reproducible and valid method to study cancer or anti-cancer proteins in endocrine neoplasms. 6 -8 The main objective of this study was to use immunohistochemical analyses in thyroid carcinoma and thyroid adenoma tissue samples to identify protein phenotypes of potential value for differentiating between benign and malignant thyroid neoplasms.
Patients and methods

PATIENTS
Consecutive patients with histologically confirmed differentiated thyroid carcinoma treated between 2001 and 2008 were identified from the Pathology Departments of the following four hospitals: Ninth Affiliated Hospital, Guangxi Medical University, Beihai, China; First Affiliated Hospital, Guangxi Medical University, Nanning, China; Guangxi People's Hospital, Nanning, China; and Guangxi Pingnan People's Hospital, Pingnan, China. All patients had undergone resection of a primary thyroid carcinoma for which histopathology slides were available for review. Paraffin-embedded tissue blocks were available for all patients. A further cohort of patients, treated surgically for thyroid adenomas between 2002 and 2008, were also identified. Patients with non-thyroid tumours, undifferentiated thyroid tumours, thyroid hyperplasia, goitre or metastasis to the thyroid gland, and those who had only undergone fine-needle aspiration or biopsy of the thyroid were excluded from the study. All available clinical, pathological, treatment and follow-up data were reviewed and updated for all patients.
TREATMENT
Primary treatment was carried out at each of the four hospitals from which records were obtained based on standard care carried out at the Ninth Affiliated Hospital, Guangxi Medical University, involving thyroidectomy with or without concomitant solid organ (pancreas, spleen, kidney and/or liver) resection as necessary to achieve complete resection of all grossly evident disease. Adjuvant treatment in the form of radiotherapy or chemotherapy was administered as part of standard care or as part of clinical trials.
PATHOLOGICAL AND CLINICAL DATA
All available operative reports and data included in the institutional pathology database and pathology reports for the primary tumours were reviewed to confirm completeness of the resection procedure. All available autopsy reports were also reviewed. A mean of five haematoxylineosin slides were evaluated per patient in conjunction with the corresponding pathology record, but there was blinding with respect to the clinical data. All histologically confirmed thyroid adenomas H-S Liang, Y-H Zhong, Z-J Luo et al.
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and carcinomas in this study were included in the analysis.
Patients' clinical data included age, sex and radiological tumour size.
TUMOUR SAMPLES
Tissue microarrays were constructed using 1 mm diameter tumour cores taken from appropriate areas of the formalin-fixed paraffin-embedded tissue blocks. The tissue cores were arrayed into a recipient paraffin block using a tissue arraying instrument (Beecher Instruments, Silver Springs, MD, USA). Serial sections 4 µm thick were cut from the tissue microarray blocks and mounted on glass slides.
IMMUNOHISTOCHEMISTRY
Using the tissue microarrays, immunohistochemical expression was investigated for the following protein markers: FHIT, peroxisome proliferator-activated receptor gamma (PPAR-γ), p16, PCNA, p53, Ki-67, MMP-2, PTTG, human telomerase reverse transcriptase (hTERT), Hector Battifora mesothelial-1 (HBME-1), MMP-7, E-cadherin and basic fibroblast growth factor (bFGF) ( Table 1) .
Tissues known to express the antigens of interest were used as positive controls and normal tissues were used as baseline controls. Sections from the tissue arrays were deparaffinized, rehydrated in graded alcohols and processed using avidin-biotin immunoperoxidase. The sections were then placed in 0.01 M citrate buffer, pH 6.0, and heated for 15 min in a microwave oven. This procedure was followed for all antibodies used in the study, with the exception of those that were incubated in pre-heated 0.05% . Following antigen retrieval, the slides were incubated in 10% normal bovine serum for 30 min, and then incubated for a further period of time in appropriately diluted primary antibody at the dilution factors, incubation times and temperatures shown in Table 1 . Diaminobenzidine was used as the chromogen and haematoxylin as the nuclear counterstain. Rates of lost cases attributable to tissue damage ranged between 1% and 10% for the different protein markers.
CLASSIFICATION
Immunoreactivity was classified as continuous data (0% undetectable through to 100% homogeneous staining) for all markers. A pathological image analysis system (DMR+Q550, Leica, Wetzlar, Germany) was used to examine and score slides independently by estimating the percentage of tumour cells that showed characteristic staining; the stained sections were all examined at high magnification (400×). Staining intensity was graded as follows: 0, achromatism; 1, light yellow; 2, light brown; and 3, dark brown and the positive cell rate within the same cell type was graded as follows: 0, < 5% positive cells; 1, 5% -25% positive cells; 2, 26% -50% positive cells; 3, 51% -75% positive cells; and 4, > 75% positive cells. The staining intensity and positive cell rate scores were than multiplied together to give the following overall scores, as follows: 0, negative (-); 1 -4, weakly positive (+); 5 -8, medially positive (++); and 9 -12, strongly positive (+++).
STATISTICAL ANALYSIS
Statistical evaluation of the data was carried out using the Statistical Package for Social Sciences (SPSS ® version 13.0; SPSS Inc., Chicago, IL, USA). Continuous data were compared using analysis of variance or the rank sum test and paired comparisons. Categorical data were compared using the χ 2 test. Factors were evaluated using logistic regression analysis, where tumour type was the dependent variable, Y, and clinical and immunohistochemical data were the independent, X, variables ( Table 2 ). The factors that showed statistical significance in a single-factor ordinal logistic regression analysis were entered into a multiple-factor Age 0 -30 years; > 30 -60 years; > 60 years X 4 -X 16 Protein markers a -; +; ++; +++ a The protein markers were: FHIT (fragile histidine triad), PPAR-γ (peroxisome proliferator-activated receptor gamma), p16, PCNA (proliferating cell nuclear antigen), p53, Ki-67, MMP (metalloproteinase)-7, HBME-1 (Hector Battifora mesothelial-1), bFGF (basic fibroblast growth factor), E-cadherin, MMP-2, PTTG (pituitary tumour-transforming gene), hTERT (human telomerase reverse transcriptase).
-, negative; +, weakly positive; ++, medially positive; +++, strongly positive.
TABLE 2: Clinical and immunohistochemistry variables (independent variables) used in logistic regression analyses to investigate their association with differentiated thyroid carcinomas and adenomas (dependent variables) Protein expression in differentiated thyroid tumours
binary logistic regression analysis. Factors were eliminated using a forward-stepwise method, with entry level set at α = 0.05 and elimination level set at α = 0.10. Predictive performance for variables was assessed using the receiver-operating characteristic (ROC) curve. The ROC used the relationship between sensitivity and specificity to calculate the best value for each variable for predicting thyroid tumour status. The variable with the best value was selected and, using successive partitioning, the predictive accuracy and best cut point for the best selected variable was calculated. A P-value < 0.05 was considered to be statistically significant.
Results
PATIENTS
The study included tissue specimens and collected data from 119 patients: 71 patients with thyroid carcinoma (45 with thyroid papillary carcinomas, 26 with thyroid follicular carcinomas) and 48 patients with thyroid adenomas.
PROTEIN MARKER IMMUNOREACTIVITY
Of the 13 protein markers evaluated, significant differences in immunoreactivity were observed between the thyroid carcinoma and thyroid adenomas groups for FHIT, p16, PCNA, p53, MMP-7, HBME-1, Ecadherin, MMP-2, PTTG and hTERT (P < 0.05; Table 3 ). There were no significant betweengroup differences for PPAR-γ, Ki-67 or bFGF. Immunoreactivity of HBME-1 and p-16 in papillary and follicular thyroid carcinoma and thyroid adenoma are shown in Fig. 1 .
MULTIPLE FACTOR BINARY LOGISTIC REGRESSION ANALYSIS
Multiple factor binary logistic regression analysis indicated that MMP-2, HBME-1, p16 and FHIT were related to differentiated (Table 4) . Goodness-of-fit indicated that the observed proportion of patients with tumours without carcinoma was similar to the predicted proportion in the derivation group (χ 2 , 10.666; degrees of freedom, 8; P = 0.221). The calibration curves for the derivation data demonstrated good calibration of the prediction rule.
PREDICTIVE VALUES OF TISSUE MARKER EXPRESSIONS
The four variables (MMP-2, HBME-1, p16 and FHIT) that attained a statistically significant level of significance in the multivariate analysis were analysed using the ROC curve, to identify the appropriate cut-off points for the prediction of malignancy. A threshold that yielded an appropriate trade-off between sensitivity and specificity (i.e. probability of 0.5 for a tumour without carcinoma) was used and the results are given in Table 5 . The best selected variable was HBME-1, with results for sensitivity, specificity, accuracy, positive predictive value and negative predictive values of 70.8%, 91.5%, 83.2%, 82.3% and 85.0%, respectively. In an attempt to increase the sensitivity of HBME-1, p16 was selected on the basis that its ROC curve area was greater than the areas for MMP-2 and FHIT. Sensitivity of the cluster, HBME-1 and p16, was 95.8% and the specificity was 95.5%.
HBME-1 AND P16 EXPRESSION IN DIFFERENT THYROID CARCINOMAS
The expressions of HBME-1 and p16 in thyroid papillary and follicular carcinomas are given Table 6 . HBME-1 expression was not significantly different for papillary and follicular carcinomas, whereas expression of p16 was significantly specific for differentiated thyroid carcinomas (P = 0.026). The expression of p16 in papillary carcinomas was mainly either weak or not detected, with no cases being strongly positive, whereas in some cases of follicular carcinoma p16 expression was strongly positive.
Discussion
The development of advanced crosssectional imaging has led to earlier diagnosis of malignant thyroid tumours, thereby increasing the challenge of differentiating Tissue microarrays for immunohistochemistry were constructed using 119 thyroid tumour samples (papillary carcinomas, n = 45; follicular carcinomas n = 26; and adenomas, n = 48) NS, not statistically significant (P > 0.05). CI, confidence interval; MMP, metalloproteinase; HBME-1, Hector Battifora mesothelial-1; FHIT, fragile histidine triad.
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benign from malignant pathology on the basis of histomorphological features alone. Most thyroid adenomas can be distinguished from carcinomas by permanent section microscopy based on well-defined, uniformly agreed-upon, pathological criteria. 9 However, the specific histological diagnosis of thyroid neoplasms is still challenging, particularly as some cases are difficult to distinguish clearly on clinical and pathological features. Diagnostic difficulties lead to misdiagnosis in some patients and create difficulties with regard to the choice of therapeutic schedules. Therefore, the identification of a simple measure to distinguish the various types of differentiated thyroid tumour will, therefore, have meaningful clinical value. 10 This study investigated 13 factors that were likely to be linked to the differential diagnosis of differentiated thyroid tumours: FHIT, PPAR-γ, p16, PCNA, p53, Ki-67, MMP-2, PTTG, hTERT, HBME-1, MMP-7, E-cadherin and bFGF. However, there is some controversy over the usefulness of immunohistochemical analysis of biomarkers in cases that are indeterminate. The purpose of this study was to determine whether immunohistochemical protein profiling of thyroid tissue may identify markers that are useful in distinguishing benign from malignant differentiated thyroid tumours.
The investigation of cell-cycle-related proteins by immunohistochemical analysis has been used to study a variety of endocrine neoplasms. The most frequently detected mutations in human malignancy involve the cell-cycle control factors p53, PCNA and Ki-67. 11, 12 In the present study there was significantly higher expression of p53 and PCNA in thyroid carcinomas compared with thyroid adenomas, however the expression of Ki-67 was not significantly different Tissue microarrays for immunohistochemistry were constructed using 119 thyroid tumour samples (papillary carcinomas, n = 45; follicular carcinomas n = 26; and adenomas, n = 48). ROC AUC, receiver-operating characteristic area under the curve; CI, confidence interval; MMP, metalloproteinase; HBME-1, Hector Battifora mesothelial-1; FHIT, fragile histidine triad. Protein expression in differentiated thyroid tumours between the two groups; immunopositivity for Ki-67 among the carcinomas was highly variable, ranging from + to +++. This result may be related to antibody selection, inability of the antibody to recognize a protein with altered configuration, or antigen retrieval methodology but it makes it unlikely that Ki-67 alone will be of practical use in differentiating benign from malignant differentiated thyroid tumours. Up-regulation of FHIT, p16 and PPAR-γ have also been shown to result in cell-cycle arrest and apoptosis. 13 -15 Previous studies have demonstrated low to absent p16 or FHIT immunoreactivity in thyroid carcinomas 4, 16 and, in the present study, their expression in thyroid carcinomas was found to be low. Conversely their expression has been found to be uniformly high in other benign endocrine tumours. 17 In the present study, there was no difference in expression of PPAR-γ between thyroid carcinomas and adenomas, which underlines the high variability in expression, although PPAR-γ has been found by others to be overexpressed in thyroid carcinomas, but only in thyroid follicular carcinomas and not in thyroid papillary or undifferentiated carcinomas. 10 This suggests that PPAR-γ may play a fundamental role in thyroid follicular tumours.
Both PTTG and hTERT have anti-degradation and anti-apotosis effects on cells and appear to be involved in cell proliferation or apotosis inactivation in human malignancy. 18 -20 In previous studies, underexpression of PTTG and hTERT was found to be associated with benign tumour biology. 18, 21, 22 There were significant differences in the positivity scores for PTTG and hTERT between thyroid adenomas and carcinomas in the present study that indicated their potential for use in differential diagnosis; the immunoreactivity for PTTG and hTERT was significantly higher in thyroid carcinoma compared with thyroid adenoma. These data suggest that PTTG and hTERT may be specific for the diagnosis of thyroid malignancy and for predicting malignant risk.
The expression of proteins associated with tumour cell invasion showed, in the present study, that MMP-2 and MMP-7 were more frequently identified in thyroid carcinoma than in thyroid adenoma, supporting the findings of previous studies and validating the value of these protein markers in distinguishing benign from malignant differentiated thyroid tumours. 23, 24 The association between E-cadherin underexpression and endocrine tumours has been reported previously, 25 and the present results indicated that E-cadherin is also underexpressed in thyroid carcinomas. Although a previous study has indicated that tumour vessel proliferation and the number of adverse pathological features in differentiated thyroid tumours are associated with bFGF immunostaining, 26 there was no significant difference between bFGF expression in thyroid carcinomas and expression in thyroid adenomas in the present study. This suggests that bFGF is not a useful tool for diagnosing malignancy in differentiated thyroid tumours.
The present study demonstrated overexpression of HBME-1 in thyroid carcinomas, with 92% of cases showing positive expression compared with 29% for thyroid adenomas. This indicates that HBME-1 could be considered a good marker for distinguishing between benign and malignant differentiated thyroid tumours.
The number of adverse morphological features displayed by differentiated thyroid tumours correlated significantly with underexpression of FHIT, p16 and E-cadherin, and with overexpression of MMP-2, PCNA, PTTG, p53, hTERT, HBME-1 and MMP-7. To the best of our knowledge, the association of these 10 factors in differentiated thyroid tumours has not been reported previously; the alliance of these factors may be a useful tool in distinguishing between benign and malignant differentiated thyroid tumours. Immunohistochemical staining of the 13 protein markers investigated in this study and the three factors of tumour classification and size, patients' gender, and age, were subject to multiple factor binary logistic regression analysis which indicated that MMP-2, HBME-1, p16 and FHIT were factors likely to be related to differentiated thyroid tumours. The correlations between malignant differentiated thyroid tumours were negative for FHIT and p16, and positive for HBME-1 and MMP-2, with HBME-1 and p16 showing the highest potential for differentiation between thyroid carcinomas and adenomas. It has previously been suggested that HBME-1 is a highly sensitive and reliable diagnostic marker for the pre-operative identification of thyroid carcinomas. 10, 27 In a study by Liu et al., 9 the accuracy of HBME-1 immunodetection in the differential diagnosis of benign and malignant thyroid lesions was 88%, which compares with 83.2% in the present study. Although HBME-1 has frequently been suggested as a very sensitive marker for papillary carcinoma, some studies have indicated that it shows low reactivity in follicular carcinoma. 28 In the present study, HBME-1 expression was not significantly higher in papillary carcinomas compared with follicular carcinomas. In comparison, a greater number of follicular carcinomas showed strong positivity to p16 compared with papillary carcinomas. Thus, the use of HBME-1 immunohistochemistry in differentiated thyroid carcinomas may increase diagnostic accuracy but, in the present study, p16 had a slightly higher sensitivity. Cluster analysis with p16 and HBME-1 in the present study found that the sensitivity increased to 95.8% and the specificity increased to 95.5%, indicating enhanced diagnostic accuracy.
In conclusion, the under-or overexpression of cell-cycle-related proteins and tumour-invasive proteins can aid the differential diagnosis of benign and malignant tumours. In the present study, expressions of the protein markers, FHIT, p16, E-cadherin, MMP-2, PCNA, PTTG, p53, hTERT, HBME-1 and MMP-7 were found to be significantly different between differentiated thyroid carcinomas and thyroid adenomas, indicating their utility as tools for differential diagnosis. In particular, HBME-1 was found to be a useful marker for distinguishing between benign and malignant differentiated thyroid tumours, and its
